HB 232 — Uniform Controlled Substances Act; revise schedules.

(7) Desomorphine;

Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, their salts, isomers (whether optical, positional,H. or geometric) and salts of isomers, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

H.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 10(MCL\KW) (1)positional, Alpha-ethyltryptamine;or geometric) and salts of isomers, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Alpha-ethyltryptamine;

(18) Diethyltryptamine;

(19) Dimethyltryptamine;

(20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 11(MCL\KW) (21)(18) Ibogaine;Diethyltryptamine;

(19) Dimethyltryptamine;

(20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);

(21) Ibogaine;

(31) Tetrahydrocannabinols, meaning tetrahydrocannabinols contained in a plant of the genus Cannabis (cannabis plant), as well as the synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of such plant, and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacologicalH. activity to those substances contained in the plant such as the following:

(A) 1 cis or trans tetrahydrocannabinol;

(B) 6 cis or trans tetrahydrocannabinol;

H.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 12(MCL\KW) (C)pharmacological 3,4activity cisto orthose transsubstances tetrahydrocannabinol.contained in the plant such as the following:

(A) 1 cis or trans tetrahydrocannabinol;

(B) 6 cis or trans tetrahydrocannabinol;

(C) 3,4 cis or trans tetrahydrocannabinol.

(iv) Personal care products that contain oil from sterilized cannabis seeds, such as shampoos, soaps, and body lotionsH. (if the products do not cause THC to enter the human body);

(v) Hemp as regulated under Sections 69-25-201 through 69-25-221;

and H.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 13(MCL\KW) (vi)lotions Any(if product derived from the hempproducts plantdo designednot forcause humanTHC ingestionto and/orenter consumption that is approved by the Unitedhuman Statesbody); Food and Drug Administration;

(v) Hemp as regulated under Sections 69-25-201 through 69-25-221;

and (vi) Any product derived from the hemp plant designed for human ingestion and/or consumption that is approved by the United States Food and Drug Administration;

(47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);

(48) 3,4-methylenedioxy-N-methylcathinone(methylone);

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 14(MCL\KW) (49)(47) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine (25B-NBOMe;(2C-P);

(48) 3,4-methylenedioxy-N-methylcathinone(methylone);

(49) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe;

Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cannabinoid found in any of the following chemical groups, whether or not substituted to any extent, or any of those groups which contain any synthetic cannabinoid salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical H.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 15(MCL\KW) salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical designation, including all synthetic cannabinoid chemical analogues in such groups:

(F) Cyclohexylphenols, being any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether H.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 16(MCL\KW) (F) Cyclohexylphenols, being any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether or not substituted in the cyclohexyl ring to any extent or in the phenolic ring to any extent;

(L) 3-carboxamide-1H-indazoles, whether or not substituted in the indazole ring to any extent and substituted to any degree on the carboxamide nitrogen and 3-carboxamide-1H-indoles, whether or not substituted in the indole H.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 17(MCL\KW) 3-carboxamide-1H-indoles, whether or not substituted in the indole ring to any extent and substituted to any degree on the carboxamide nitrogen;

(2) Flualprazolam, H.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 18(MCL\KW) (2) Flualprazolam, 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4 ]benzodiazepine;

(6) 4-methylaminorex (also known as 2-amino-4-methyl-5-phenyl-2-oxazoline);

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 19(MCL\KW) (7)(6) N-ethylamphetamine;4-methylaminorex (also known as 2-amino-4-methyl-5-phenyl-2-oxazoline);

(7) N-ethylamphetamine;

(B) The compounds covered in this paragraph (9) include, but are not limited to, any material, compound, mixture or preparation which contains any quantity of a synthetic cathinone found in any of the following compounds, whether or not substituted to any extent, or any of these compounds which contain any synthetic cathinone, or salts, isomers, or salts of isomers, whenever the existence of such salts, isomers or salts of isomers H.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 20(MCL\KW) any synthetic cathinone, or salts, isomers, or salts of isomers, whenever the existence of such salts, isomers or salts of isomers is possible, unless specifically excepted or listed in another schedule:

SECTION 2.

Section 41-29-115, Mississippi Code of 1972, is amended as follows:

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 21(MCL\KW) 41-29-115.SECTION 2.

Section 41-29-115, Mississippi Code of 1972, is amended as follows:

41-29-115.

(viii) Metopon;

(ix) Morphine;

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 22(MCL\KW) (x)(viii) OpiumMetopon; extracts;

(ix) Morphine;

(x) Opium extracts;

(5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy).

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 23(MCL\KW) (c)(5) Opiates.Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy).

(c) Opiates.

(16) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butane;

(17) Moramide-intermediate, 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 24(MCL\KW) (18)(16) OliceridineMethadone-intermediate, (N-[(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-4-cyano-2-dimethylamino-4,4-diphenyl oxaspiro[4.5]decan-9-yl]ethyl})amine);butane;

(17) Moramide-intermediate, 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;

(18) Oliceridine (N-[(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6- oxaspiro[4.5]decan-9-yl]ethyl})amine);

(d) Stimulants.

Any material, compound, mixture, or preparation which contains any quantity of the following substances:

(1) Amphetamine, its salts, optical isomers, and salts of its optical isomers;

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 25(MCL\KW) (2)(d) PhenmetrazineStimulants. and its salts;

Any material, compound, mixture, or preparation which contains any quantity of the following substances:

(1) Amphetamine, its salts, optical isomers, and salts of its optical isomers;

(2) Phenmetrazine and its salts;

(2) Nabilone [other names include:

(+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a- hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one].

(g) Immediate precursors.

Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 26(MCL\KW) (1)(2) AmphetamineNabilone and[other methamphetaminenames immediateinclude: precursor:

(+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a- hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one].

(g) Immediate precursors.

Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

(1) Amphetamine and methamphetamine immediate precursor:

SCHEDULE IV (a) Narcotic drugs.

Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains limited quantities of the following narcotic drugs, or any salts thereof:

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 27(MCL\KW) (1)SCHEDULE NotIV more(a) thanNarcotic onedrugs. (1) milligram of difenoxin and not less than twenty-five (25) micrograms of atropine sulfate per dosage unit;

Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains limited quantities of the following narcotic drugs, or any salts thereof:

(1) Not more than one (1) milligram of difenoxin and not less than twenty-five (25) micrograms of atropine sulfate per dosage unit;

(8) Chloral betaine;

(9) Chloral hydrate;

(10) Chlordiazepoxide and its salts, but does not include chlordiazepoxide hydrochloride and clidinium bromide or chlordiazepoxide and esterified estrogens;

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 28(MCL\KW) (11)(8) Clobazam;Chloral betaine;

(9) Chloral hydrate;

(10) Chlordiazepoxide and its salts, but does not include chlordiazepoxide hydrochloride and clidinium bromide or chlordiazepoxide and esterified estrogens;

(11) Clobazam;

(H. * * *31) Loprazolam;

B.

No.

232 *HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R911SG PAGE 29(MCL\KW) ( * * *31) Loprazolam;

H.( * * *36) Meprobamate;

B.

No.

232 *HR26/R911* ~ OFFICIAL ~ 22/HR26/R911 PAGE 29(MCL\KW) ( * * *36) Meprobamate;

( * * *56) Zaleplon;

( * * *57) Zolpidem;

( * * *58) Zopiclone.

(c) Fenfluramine.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 30(MCL\KW) (d)( Lorcaserin.* * *56) Zaleplon;

( * * *57) Zolpidem;

( * * *58) Zopiclone.

(c) Fenfluramine.

(d) Lorcaserin.

(13) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

(f) Other substances.

(1) Pentazocine;

(2) Butorphanol (including its optical isomers);

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 31(MCL\KW) (3)(13) EluxadolineSPA (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopr((-)-1-dimethylamino-1,2-diphenylethane). opyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-meth oxybenzoic acid);

(f) Other substances.

(1) Pentazocine;

(2) Butorphanol (including its optical isomers);

(3) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopr opyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-meth oxybenzoic acid);

Any compound, mixture or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the H.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 32(MCL\KW) free anhydrous base or alkaloid, in limited quantities as set forth below, which also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

Unless specifically excepted or listed in another schedule, any material, compound, mixture or preparation whichH. contains any quantity of the following substance, including its salts, isomers and salts of isomers:

Pyrovalerone.

(e) Depressants.

Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, H.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 33(MCL\KW) mixture or preparation which contains any quantity of the following substancessubstance, having a depressant effect on the central nervous system, including theirits salts, isomers and salts of isomers:

Pyrovalerone.

(e) Depressants.

Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of isomers:

(f) Any material, compound, mixture or preparation which contains any quantity of a Schedule V controlled substance and is listed as an exempt substance in 21 CFR, Section 1308.22, 1308.24, 1308.26, 1308.32 or 1308.34, shall be exempted from the provisions of the Uniform Controlled Substances Law.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG PAGE 34(MCL\KW) SECTION(f) 5.Any material, compound, mixture or preparation which contains any quantity of a Schedule V controlled substance and is listed as an exempt substance in 21 CFR, Section 1308.22, 1308.24, 1308.26, 1308.32 or 1308.34, shall be exempted from the provisions of the Uniform Controlled Substances Law.

ThisSECTION act5. shall take effect and be in force from and after July 1, 2022.

Section 41-29-137, Mississippi Code of 1972, as amended by Senate Bill No.

2095, 2022 Regular Session, is amended as follows:

41-29-137.

(a) (1) Except when dispensed directly by a practitioner, other than a pharmacy, to an ultimate user, no controlled substance in Schedule II, as set out in Section 41-29-115, may be dispensed without the written valid prescription of a practitioner.

A practitioner shall keep a record of all controlled substances in Schedule I, II and III administered, dispensed or professionally used by him otherwise than by prescription.

(2) In emergency situations, as defined by rule of the State Board of Pharmacy, Schedule II drugs may be dispensed upon the oral valid prescription of a practitioner, reduced promptly to writing and filed by the pharmacy.

Prescriptions shall be retained in conformity with the requirements of Section 41-29-133.

No prescription for a Schedule II substance may be refilled unless renewed by prescription issued by a licensed medical doctor.

(b) Except when dispensed directly by a practitioner, other than a pharmacy, to an ultimate user, a controlled substance H.

B.

No.

232 *HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R911SG PAGE 35(MCL\KW) included in Schedule III or IV, as set out in Sections 41-29-117 and 41-29-119, shall not be dispensed without a written or oral valid prescription of a practitioner.

The prescription shall not be filled or refilled more than six (6) months after the date thereof or be refilled more than five (5) times, unless renewed by the practitioner.

(c) A controlled substance included in Schedule V, as set out in Section 41-29-121, shall not be distributed or dispensed other than for a medical purpose.

(d) An optometrist certified to prescribe and use therapeutic pharmaceutical agents under Sections 73-19-153 through 73-19-165 shall * * * have the prescriptive authority granted in Section 73-19-157.

(e) Administration by injection of any pharmaceutical product authorized in this section is expressly prohibited except when dispensed directly by a practitioner other than a pharmacy.

(f) (1) For the purposes of this article, Title 73, Chapter 21, and Title 73, Chapter 25, Mississippi Code of 1972, as it pertains to prescriptions for controlled substances, a "valid prescription" means a prescription that is issued for a legitimate medical purpose in the usual course of professional practice by:

(A) A practitioner who has conducted at least one (1) in-person medical evaluation of the patient, except as otherwise authorized by Section 41-29-137.1;

or (B) A covering practitioner.

232 *HR26/R911**HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R91122/HR26/R911SG ST:PAGE 36(MCL\KW) (2) (A) "In-person medical evaluation" means a medical evaluation that is conducted with the patient in the physical presence of the practitioner, without regard to whether portions of the evaluation are conducted by other health professionals.

(B) "Covering practitioner" means a practitioner who conducts a medical evaluation other than an in-person medical evaluation at the request of a practitioner who has conducted at least one (1) in-person medical evaluation of the patient or an evaluation of the patient through the practice of telemedicine within the previous twenty-four (24) months and who is temporarily unavailable to conduct the evaluation of the patient.

(3) A prescription for a controlled substance based solely on a consumer's completion of an online medical questionnaire is not a valid prescription.

(4) Nothing in this subsection (f) shall apply to:

(A) A prescription issued by a practitioner engaged in the practice of telemedicine as authorized under state or federal law;

or (B) The dispensing or selling of a controlled substance pursuant to practices as determined by the United States Attorney General by regulation.

(g) This section does not apply to any of the actions that are lawful under the Mississippi Medical Cannabis Act and in compliance with rules and regulations adopted thereunder.

H.

B.

No.

232 *HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R911SG PAGE 37(MCL\KW) SECTION 6.

This act shall take effect and be in force from and after its passage.

H.

B.

No.

232 *HR26/R911SG* ~ OFFICIAL ~ 22/HR26/R911SG ST:

revise PAGE 3538 (MCL\KW) schedules.